{"id":"NCT00419094","sponsor":"UCB Pharma","briefTitle":"Conversion to Monotherapy Study With Keppra XR for Partial Seizures","officialTitle":"A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2007-01-08","resultsPosted":"2010-12-20","lastUpdate":"2014-09-05"},"enrollment":228,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Keppra XR","otherNames":[]},{"type":"DRUG","name":"Keppra XR","otherNames":[]}],"arms":[{"label":"Keppra XR 1000 mg/day","type":"EXPERIMENTAL"},{"label":"Keppra XR 2000 mg/day","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.","primaryOutcome":{"measure":"The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase","timeFrame":"112 days","effectByArm":[{"arm":"Keppra XR 2000 mg/Day","deltaMin":0.375,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":45,"countries":["United States","Mexico","Poland","Russia"]},"refs":{"pmids":["22516508"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":57},"commonTop":["somnolence","headache","convulsion","dizziness","irritablility"]}}